21 November 2026 • 6 min read
No source here mentions brain-computer interfaces by name, so the pathway below is the general route for an investigational medical device. CDSCO's page on medical devices says all medical devices in India are regulated under the Drugs & Cosmetics Act, 1940 and the Medical Devices Rules, 2017 made under it. Its FAQ confirms that all medical devices are regulated under those Rules. 2,3
For a clinical trial, CDSCO lists a step called permission to conduct clinical investigation of an investigational medical device. The applicant files Form MD-22 on the Sugam online portal and receives permission in Form MD-23. 2
The second gate is ethical review. CDSCO's MD-22 checklist asks for an Ethics Committee approval letter, and the ICMR National Ethical Guidelines set how such committees work. 4,7
Why it matters (our view)
Founders should treat classification as the first task, because the class decides who licenses and what evidence is needed.
Build ethics and consent documents alongside the technical file, since the MD-22 checklist asks for both.
Confirm current rules on CDSCO and ICMR pages before filing, as both bodies update guidance.
The Rules define an investigational medical device, other than an in vitro diagnostic, as one that has no predicate device. The definition also covers a licensed device that claims a new intended use, new population, new material or major design change, and that is being assessed in a clinical investigation. 1
A device that senses or stimulates the brain would need to be checked against this definition. The Rules define an active medical device as one whose operation depends on electrical or other energy not generated by the human body. They also define an active diagnostic device as one that supplies information for detecting, diagnosing or monitoring a condition. 1
CDSCO's definition of a medical device includes software and accessories. It covers use for diagnosis, monitoring, treatment or alleviation of disease, and for assistance for injury or disability. It also covers support of a physiological process. 2
CDSCO says medical devices fall into four classes by risk, set out in Part I of the First Schedule of the Rules. Class A is low risk, Class B low moderate risk, Class C moderate high risk and Class D high risk. 2
The Rules define an invasive device as one that penetrates inside the body, in whole or part, through a body orifice or through the surface of the body. That definition is the hook for separating implanted from surface devices. It also defines long term use as intended continuous use of more than thirty days. 1
The sources reviewed do not say which class a specific EEG or BCI product receives. The class-wise device list sits in the IPC guidance document, which this article could not read in full. CDSCO says it updates its classification list from time to time, and it offers a startup consultation cell for questions on regulatory status. 2,3,8
CDSCO's checklist for Form MD-22 opens with a cover letter stating whether the study is pilot, pivotal or post-marketing, along with its objective. It then requires the application, a fee challan and a justification for the proposed class of device with supporting documents. 4
The technical part covers design input, output and control documents, design verification and validation reports, and an Essential Principles checklist. It also covers device specifications with test reports. Mechanical, electrical, reliability, software verification and validation and ex vivo tests are listed wherever applicable. 4
Other items include a risk management report, biocompatibility and animal performance study data, proposed labelling and stability data if any. The clinical documents are the Investigator's Brochure, Clinical Investigational Plan, Case Report Form, Informed Consent Form and an undertaking by the investigator, all as per the Seventh Schedule. 4
| Step | Form or body | Detail | Source |
|---|---|---|---|
| Clinical investigation permission | Form MD-22 / MD-23 | Filed on Sugam portal; permission granted in MD-23 | 2 |
| Test licence to manufacture | Form MD-12 / MD-13 | For clinical investigation, test, evaluation | 2 |
| Test licence to import | Form MD-16 / MD-17 | Valid three years from issue | 3 |
| Device with no predicate | Form MD-26 / MD-27 | Applied after clinical investigation | 2 |
| Central Licensing Authority | Drugs Controller General (India) | Handles clinical investigation approval | 3 |
| Ethics approval | Ethics Committee | Approval letter is an MD-22 checklist item | 4 |
The ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants were issued in October 2017. They say the guidelines must be followed by institutions, ethics committees, researchers and sponsors or funding agencies. They apply to research in India involving human participants, their biological material and data. 6,7
The guidelines require written informed consent from the participant or the legally acceptable representative, in simple language approved by the ethics committee. The committee decides whether review is exempted, expedited or full committee, based on risk. Serious adverse events must reach the committee within 24 hours of knowledge, with a relatedness report within 14 days. 6
Sponsors must budget for insurance or compensation for research-related injury. The guidelines also contain a section on device trials and one on vulnerable groups, such as individuals with mental illness or cognitive impairment. Both matter for neurological BCI studies. 6,7
An Indian team building a brain-computer interface should treat the CDSCO route as the default. CDSCO says the Drugs Controller General (India) is the Central Licensing Authority, and that it handles clinical investigation approval and approval of devices with no predicate device. Test licences for manufacture or import of devices for clinical investigation are also granted centrally, in Forms MD-13 and MD-17, valid for three years. 3
Applications go through online portals. CDSCO's FAQ names www.cdscomdonline.gov.in and www.nsws.gov.in. Fees follow the Second Schedule, and there is no provision for refund if an application is withdrawn. 3
Two ICMR points shape the plan. Clinical studies on human participants should be registered prospectively with the Clinical Trial Registry - India, and this is mandatory for regulatory trials. For multicentre work, a common ethics review by a designated committee can cut approval time, though each local committee must still look at site-specific concerns. 6
Startups can write to CDSCO's Public Relation Office cell at startupinnov@cdsco.nic.in for guidance on the regulatory pathway. Once a trial ends, a device without a predicate applies in Form MD-26 for permission to manufacture or import. 2,3
Form MD-22, filed on the Sugam online portal, is used to seek permission to conduct clinical investigation of an investigational medical device. Permission is granted in Form MD-23. 2
CDSCO says devices fall into four risk classes under Part I of the First Schedule of the Medical Devices Rules, 2017: Class A low risk, Class B low moderate, Class C moderate high and Class D high risk. 2
Yes. CDSCO's MD-22 checklist lists an Ethics Committee approval letter, and the ICMR guidelines set how such committees review research. 4,7
CDSCO's FAQ says the Drugs Controller General (India) is the Central Licensing Authority for medical devices in India. 3
How this page was made: written with AI from the sources above, read on 21 November 2026. Every figure was checked against the source it cites; lines under "Why it matters" are our view. Editorial standards.
Have a question about deeptech in India? Ask Kriyā: it answers from our dated sources, and the first answers are free.
Ask Kriyā